The Department of Defense (DOD) is soliciting applications for the Duchenne Muscular Dystrophy Research Program's Clinical/Translational Research Award (CTRA) for fiscal year 2025. The funding opportunity aims to support advanced translational research that accelerates promising ideas in Duchenne muscular dystrophy (DMD) into clinical applications, particularly for therapies effective across all ages. Eligible applicants include both domestic and foreign organizations, and they may apply for two funding levels based on project complexity, with a total allocation of approximately $8.56 million for the program. Key submission deadlines include a pre-application due by July 25, 2025, and a full application due by August 8, 2025. Review processes encompass compliance checks, peer reviews, and programmatic assessments. The program strongly encourages collaborations, especially with early-career investigators, and outlines responsibilities for Principal Investigators. Essential components of the application include project narratives, statements of work, and detailed budget justifications. The initiative aligns with the DOD's mission to enhance healthcare for service members and their families, aiming to significantly improve DMD treatment outcomes and patient quality of life.